【CFA Society Japan Webinar】ESG in Pharma

When:  Jan 23, 2024 from 07:00 PM to 08:30 PM (JP)
Associated with  CFA Society Japan

CFA Society Japan Webinar

ESG in Pharma

Date & Time: Tuesday, January 23, 2024, 19:00-20:30JST

Format: Zoom webinar


Mr. Bram Wagner (Investor Engagement Officer, the Access to Medicine Foundation)

Ms. Sandra Nobre  (Head of Business Development, Medicines Patent Pool)

Fee: Free for all participants
PL Credit: 1.5
Topics: Investment Management Strategies, Investment Products & Asset Classes

(This is a Global Passport accredited event.) 



We will invite two special organizations, The Access to Medicine Foundation and The Medicines Patent Pool (MPP) as speakers to talk about ESG in Pharma. The Access to Medicine Foundation is an independent non-profit organization to transform the healthcare ecosystem by motivating and mobilizing companies to expand access to their essential healthcare products in low- and middle-income countries. While MPP is a United Nations-backed public health organization working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries.

Session 1: The Access to Medicine Foundation "ESG in Pharma: Unveiling Opportunities for Investors in Access to Medicine" (30min)

Speaker: Mr. Bram Wagner, Investor Engagement Officer

Session 1 Outline

1. Unlocking Medicine Access:

- Discover our mission for global change.


2. Global Medicine Access Unveiled: Challenges and Solutions

- Join us as we uncover the critical challenges and disparities in global medicine access, and opportunities for greater equity in global medicine access.


3. The Foundation's tried and tested change-making model

- Experience our unique change-making model and the power of collaborative solutions.


4. The Investor's Role in Driving Change

- Learn how investors play a pivotal role in steering change within the pharmaceutical landscape.


5. Mutual Benefits for Investors and Pharma Companies

- Uncover the shared benefits that come from investor engagement with pharmaceutical companies.


6. Conclusions and Call to Action

- Conclude with insights, inspiration, and a clear call to action, empowering investors to be part of the solution for a better, more accessible future.


Session 2: The Medicines Patent Pool "Introduction to MPP" (30min)

Speaker: Mr. Parag Nimbolkar, Business Development Manager, In-licensing (Geneva)

Session 2 Outline

Sandra will talk about the work they are doing towards ascribing value to their Impact.

Q&A (30min)



Mr. Bram Wagner
Bram serves as Investor Engagement Officer at the Access to Medicine Foundation. He manages the Foundation's relationships with institutional investors, collaborating closely with healthcare analysts and ESG professionals. His focus is on supporting investors in engaging with pharmaceutical companies and enhancing their understanding of access to medicine issues.

Bram is a pharmacist by training and holds the CFA Certificate in ESG Investing. With a strong foundation in pharmaceuticals, finance, and sustainable investing, Bram brings a unique and informed perspective to the intersection of healthcare and investment. His work reflects a commitment to fostering understanding and collaboration for meaningful change within the pharmaceutical industry.


Ms. Sandra Nobre  

Head of Business Development, Medicines Patent Pool 

Sandra Nobre joined the Medicines Patent Pool, a United Nations Public Health Organization working to increase access to essential medicines in LMICs (low-middle income countries), in October 2018, as Head of Business Development. 
Sandra has had a 20-year successful career within the pharmaceutical industry in companies such as Pfizer and Novartis and spent her lasts 8 years in the industry as Senior Director, Global Business Development at Takeda. 
Acquired throughout her career she also has a deep knowledge of the global healthcare ecosystem that she fully integrates in her current Public Health oriented role. 
Sandra earned a Master of Science in Pharmaceutical Chemistry and post-graduated in Biotechnology having completed some years later a Diploma of Advanced Studies in Corporate Social Responsibility and an MBA in International Management.
While in MPP Sandra was instrumental in strengthening its role in the HIV and other infectious diseases space and in securing new licensing deals namely for the 3 Covid oral anti-virals from Shionogi, MSD and Pfizer and the Long-Acting Cabotegravir injectable from ViiV.
Sandra enjoys working internationally and integrates well with multicultural and multinational environments and passionately integrates in her way of operating procedures ethically leading to sustainability.


If you wish to attend this webinar, please register from the link below.


 After registering, you will receive a confirmation email containing information about joining the webinar.

CFA Society Japan
[email protected]